Abstract

Given the COVID-19 virus epidemic and vaccination increment all around the world, after surveying the vaccination side effects it was clarified that 72.6% of individuals reported at least one symptom after the first and second injection of Pfizer-BioNTech vaccine which pain at injection site, fever and myalgia/arthralgia were most common among these symptoms. Furthermore, most common severe side effects like fever > 39 °C were perceived more after the second dose of vaccine. In the study of identifying body’s physiologic changed, heart rate variability (HRV) decreased after the first dose and the second dose without having considerable changes in resting heart rate (RHR) and respiratory rate (RR) and the duration of sleep also declined up to 4 days of both vaccination doses. Plus, Local and systemic reactogenicity were more intense after the second dose. Following the COVID-19 vaccination, various allergic reactions also started to promote all around the countries, a questionnaire was adjusted in Toronto-Canada and 65 patients had PEG-ASNase allergy. Rapid reactions like anaphylaxis occur following the first dose of Pfizer mRNA COVID-19 vaccine. In a study consisted of 175 individuals, 21 of them were afflicted with anaphylaxis and a number of 83 individuals experienced non-anaphylaxis allergic reactions but still further studies are required in order to identify the relation between anaphylaxis and COVID-19 vaccines. Disease background is an outstanding factor to intensify COVID-19 infection. In a research, a 40-year old woman who had experienced left peripheral facial nerve palsy 4 years ago and in another research 8 adolescents who visited Nicklaus Children’s Hospital with perimyocarditis within 4 days of receiving the second dose of BNT162b2 vaccine, were investigated in this context. In terms of gender and age relation, a study was carried out on German residents of Bavaria between Jan 9 to Apr 11, 2021 and, it was clarified that both doses of the BioNTech-Pfizer’s BNT162b2 are highly effective against the infection and adverse events of COVID-19 virus in elder people and according to another report, 82% of individuals experienced at least one symptom Following the first dose of Comirnaty vaccine which was more common in women under the age 55 (64%). In a study which was carried out among the workers of Mazandaran University of Medical Sciences in order to identify the side effects of the Sputnik V vaccine, a number of 3236 individuals in the 19-78 age range with the mean age of 38 years old submitted their report. According to a research which was conducted in Bavaria, Germany, the mortality rate was considerably lower in individuals who had received vaccination in relation to not vaccinated individuals, however, 3 death cases were reported in individuals who suffered from comorbidities after receiving the Sputnik vaccine which was considered to be irrelevant to vaccination. A research was conducted to evaluate the effectiveness of Robust antibody after the first and second dose in individuals aged between 70 and 90. From 99 individuals who received the first dose of their vaccination after 3 weeks the existence of Robust antibody was proven in 95% of them and from 86 individuals who received their vaccine’s second dose after 3 weeks, all of them showed a positive result in the test. Furthermore, in another study from 75% of old individuals who were vaccinated at least once, the first dose led into COVID-19 infection decrease and had an effectiveness of 52% in clinical experiments. According to another report, the antibody was observed in 92% of individuals 21 days after the first dose and also in 97% of them 21 days after the second dose it was concluded that Symptoms following vaccination are not unusual and they occur because of body’s immune system response.